Abnormal energy metabolism due to mitochondrial dysfunction is thought to be a major contributor to the progression of Parkinson’s disease (PD). We employed 31P MRS-MT technique at 7T to quantify key bioenergetic parameters in the occipital lobe of people with PD (PWPs). Significantly lower intracellular ATP concentrations together with elevated ATPase activity was found in PWPs; suggesting that augmented ATPase enzymatic activity may represent a compensatory mechanism to bioenergetic deficits that occur in PD. The FDA-approved drug, ursodeoxycholic acid (UDCA), shown to have energy-enhancing properties was evaluated for its effect on improving neuroenergetics in PWPs using the 31P MRS-MT approach.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords